Navigation Links
Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Date:2/24/2009

PARIS, January 24 /PRNewswire/ -- The European Commission has granted marketing authorisation for Servier's Valdoxan(R) /Thymanax(R) (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes.

"There is still great scope for improved therapies to treat the devastating effects of depression," said Professor Goodwin from Warneford Hospital, Oxford, United Kingdom. "Valdoxan is an innovative, new approach to the management of depression that compares favourably to existing treatments. It has proven, sustained efficacy across a wide range of depressed patients, including those who are most severely depressed."

Valdoxan, one 25 mg tablet taken at bedtime, offers new hope for the 33 million people in Europe suffering from major depressive episode. Valdoxan's powerful antidepressant efficacy combined with its good safety and tolerability profile is a result of its unique receptor profile. Valdoxan is the first antidepressant with melatonin receptor (MT1) and (MT2) agonist properties and 5-hydroxytryptamine (serotonin) receptor 2C (5-HT2C) antagonist properties. This unique receptor profile of Valdoxan allows for the first time the restoration of the circadian rhythms of depressed patients.(1)

Valdoxan: significant antidepressant efficacy from the start to the end of treatment

The European approval of Valdoxan is based on both short and long-term results from a large, comprehensive, international development programme including almost 6,000 adult patients with depression. The results demonstrate the superior efficacy of Valdoxan as compared with placebo, selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitor (SNRI) treatments and also show that:

    - Valdoxan has proven efficacy whatever the intensity of symptoms, in
      moderately and severely depressed adult patients (18-65 years old)
      presenting a first or recurrent episode of depression(2)

    - Valdoxan has demonstrated efficacy at every step of depression
      treatment, showing superior clinical improvement within the first week
      of treatment, as reported by both physicians and patients(3),(4)

    - Valdoxan is effective against all the core symptoms of depression,
      including depressed mood, anxiety, feeling of guilt, psychomotor
      retardation, sleep disturbances, and daytime fatigue, leading depressed
      patients to a more complete and sustained remission(5)

    - Valdoxan has been proven to significantly reduce the incidence of
      relapse in depressive patients over the long term(4)

    - Valdoxan preserves sexual functioning, is weight neutral and offers a
      favourable tolerability profile, thus resulting in better adherence and
      remission in depressed patients(6)

    - Valdoxan is easy to use from beginning to end: a simple dose of one 25
      mg tablet taken orally at bedtime, without discontinuation symptoms at
      the end of treatment.(7)

"Valdoxan has the potential to relieve the symptoms of depression with a reduced risk of significant adverse effects," said Professor Goodwin. "With noticeable clinical improvement as early as the first week of treatment, Valdoxan represents an advance for depressed patients who today expect a more complete remission."

Valdoxan: a major therapeutic advance in management of depression through the restoration of circadian rhythms

Valdoxan is the result of an advanced pharmacological research programme involving investigation centres all around the world. It is the first antidepressant that simultaneously acts as a MT1 and MT2 melatonergic receptors agonist and a 5-HT2C antagonist. As a result, Valdoxan resynchronises circadian rhythms that are profoundly disrupted in depressed patients.(8)

"Valdoxan's mechanism of action is unlike those of the commonly-prescribed antidepressants, the SSRIs and SNRIs, as Valdoxan exerts its antidepressant efficacy without having an impact on serotonin levels," pointed out Professor Racagni from the University of Milan, Italy.

The recommended dose of Valdoxan is one tablet of 25 mg taken once daily, orally at bedtime.

Following approval from the European Commission, Valdoxan is expected to become commercially available in European countries in the coming months.

Valdoxan(R) was discovered and developed by Servier, France's leading independent pharmaceutical company.

References

(1) Lôo H, Hale A, D'haenen H. Int Clin Psychopharmacol. 2002;17:239-247.

(2) Montgomery SA, Kasper S. Int Clin Psychopharmacol. 2007;22:283-291

(3) Kasper S, Laigle L, Baylé F. Eur Neuropsychopharmacol. 2008;18(suppl4):S336.Abstract P2c022.

(4) Goodwin G, Rouillon F, Emsley R. Eur Neuropsychopharmacol. 2008;18(suppl4):S338. Abstract P2c025.

(5) Lemoine P, Guilleminault C, Alvarez E. J Clin Psychiatry. 2007;68:1723-1732.

(6) Kennedy SH, Rizvi S, Fulton K, Rasmussen J. J Clin Psychopharmacol. 2008;28:329-333.

(7) Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Int Clin Psychopharmacol. 2004;19:271-280

(8) Leproult R, Van Ondergergen A, L'Hermite-Balériaux M, Van Cautert E, Copinschi G. Clin Endocrinol. 2005;63:298-304.


'/>"/>
SOURCE Servier
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
2. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
3. BioLife Solutions Granted European Biopreservation Patent
4. ScinoPharm Granted US Patent for Novel Crystal Forms
5. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
6. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
7. Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Biopure Granted Additional 180 Day Compliance Period by NASDAQ
10. Skinvisible Patent Granted in Australia
11. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Genedata, a leading ... today announced the establishment of Genedata Limited as a new subsidiary in the ... expert in life science informatics. Creating the UK subsidiary reinforces Genedata’s commitment to ...
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of ... use, in multiple areas of medicine, due to their differentiating characteristics. Stem cells are ... have the ability to be induced to become tissue or organic-specific cells with special ...
(Date:2/21/2017)... ... February 21, 2017 , ... VetStem Biopharma, ... its headquarters laboratory in Poway, California. Based upon 12 years of knowledge ... personnel and consultants, VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing ...
(Date:2/21/2017)... Wash. and VANCOUVER, British Columbia ... OGXI ) today announced that apatorsen results from two ... Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held ... Orlando . Clinical data from trials in bladder and ... when administered in combination with standard-of-care treatments. ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017  EyeLock LLC, a market leader of ... paper " What You Should Know About Biometrics in ... user authenticity is a growing concern. In traditional schemes, ... However, traditional authentication schemes such as username/password suffer from ... authentication offers an elegant solution to the problem of ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
Breaking Biology News(10 mins):